SingleBioregulators

Vesugen 20mg

A synthetic vascular bioregulator tripeptide (Lys-Glu-Asp) investigated for endothelial health, gene expression, and vascular aging.

Mechanism

Vesugen is hypothesized to act epigenetically within vascular endothelial cells, altering the expression of regulatory genes including Ki-67, endothelin-1, connexin, and SIRT1.

Dosing

Initial research protocols document an introductory dose of 500 mcg administered once daily.

Reconstitution

Adding 3.0 mL of bacteriostatic water to a 20 mg vial produces a reconstituted solution with an approximate concentration of 6.67 mg/mL.

Storage

Keep lyophilized vials frozen at -20 °C, and once reconstituted, maintain the liquid solution between 2 and 8 °C protected from light without refreezing.

Mix & measure Vesugen 20mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Vesugen 20mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration6.67mg/mL

Draw volume0.075mL

On the syringe7.50units

Total doses in vial: 40.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Week 1	500 mcg (1× daily)	~7.5 units (~0.075 mL)
Week 2	1,000 mcg (1× daily)	15 units (0.15 mL)
Week 3	1,500 mcg (1× daily)	~22.5 units (~0.225 mL)
Weeks 4–8+	1,500–2,000 mcg (1× daily)	~22.5–30 units (~0.225–0.30 mL)

Reconstitution Steps

1
Clean the rubber stopper of the 20 mg Vesugen vial with an alcohol wipe and allow it to dry.
2
Draw 3.0 mL of bacteriostatic water into a sterile mixing syringe.
3
Introduce the bacteriostatic water into the vial slowly, aiming the stream along the inner glass wall to avoid turbulence.
4
Gently rotate or roll the vial until the lyophilized powder is completely dissolved; avoid shaking.
5
Affix a label noting the reconstitution date and resulting 6.67 mg/mL concentration, then refrigerate immediately at 2–8 °C.

Supplies Needed

Peptide Vial

Contains 20 mg of lyophilized Vesugen powder for experimental reconstitution.

Insulin Syringes (U-100)

Used for precise measurement and subcutaneous delivery of low-volume research doses (30-unit or 50-unit syringes recommended).

Bacteriostatic Water

Provides 3.0 mL of sterile diluent preserved with benzyl alcohol for multi-dose reconstitution.

Alcohol Swabs

Used to sanitize the vial stopper prior to needle entry and cleanse the designated injection site.

Why researchers study it

Vascular and endothelial function

Cardiovascular aging and tone

Microcirculation and vascular elasticity

Epigenetic regulation in vascular tissues

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Vesugen is a short synthetic tripeptide consisting of lysine, glutamic acid, and aspartic acid (KED). Identified initially within the framework of Khavinson peptide bioregulation studies, it was modeled after the active biological components found in crude vascular tissue extracts such as Ventfort. As a targeted cytogen, it is investigated primarily for its structural influence on vascular endothelial integrity. Preclinical research focuses on how this short amino acid chain interacts with vascular cellular structures, particularly evaluating its role in gene expression markers relevant to endothelial health, cellular replication, and arterial function. It is predominantly handled as an experimental model for vascular aging, tone, and cellular longevity. All documented handling metrics reflect early laboratory paradigms rather than validated human clinical interventions. Vesugen remains an unapproved research compound intended strictly for controlled laboratory experiments and scientific evaluation.

References

1.Khavinson et al., PubMed, 2020 — Overview of Khavinson peptide bioregulators and synthetic short peptides including KED
2.Khavinson et al., PubMed, 2014 — Vascular tissue-derived peptide extracts and synthetic KED tripeptide characterization
3.Khavinson et al., PubMed, 2017 — Epigenetic regulation and gene expression modulation (Ki-67, endothelin-1, SIRT1) by short peptides in endothelial cells